Chien-Wei Su is an expert in Hepatology at Taipei Veterans General Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Chien-Wei Su in the top 1% of experts worldwide for Liver Neoplasms and Carcinoma. Chien-Wei Su has authored 291 publications, the most recent in 2025, and is an investigator in 3 clinical trials. SLR score: 743 (community average: 125). How the SLR is computed.

LeadR Profile

743 ScienceLeadR Reputation 743
Network Map

Hepatology

Subspecialties: Gastroenterology - Oncology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2025

Source: PubMed

Taipei Veterans General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 291

Citations

Citations: 8 355 1st author: 26 Last author: 35 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Unravelling the heterogeneous HCC risk in indeterminate chronic hepatitis B.
PMID 40829868 — gastroenterology, hepatitis, chronic, hepatitis b, hepatitis b, chronic, hepatitis
Gut20250
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular Carcinoma.
PMID 40755008 — liver diseases, carcinoma, hepatocellular, neoplasms, liver, immunotherapy, liver neoplasms, therapeutics
Clin Mol Hepatol20250
Differential Prognostic Impact of Tumor Burden Score on Hepatocellular Carcinoma Patients with Variable Physical Performance Status.
PMID 40153238 — carcinoma, hepatocellular, serum, gastroenterology, neoplasms, tumor burden
Dig Dis Sci20250
The frontline of metabolic dysfunction‑associated steatotic liver disease (MASLD): More to be discovered.
PMID 40626331 — liver diseases, liver
J Chin Med Assoc20250
Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score.
PMID 40510573 — carcinoma, hepatocellular, neoplasms, liver, immunotherapy, tumor burden, response evaluation criteria in solid tumors, proportional hazards models
Liver Cancer20251

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 2
Phase 4 1

By status:

Unknown 2
Completed 1

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map